Why the study?
Atrial fibrillation presents significant public health challenges due to complex mechanisms, prompting investigation into mitochondrial dysfunction and cardiac fibrosis at the molecular level.
A 3D fast-paced hiPSC-CM organoid model successfully recapitulates the functional impairment and mitochondrial-fibrotic remodeling characteristic of early atrial fibrillation.
No immediate clinical implications for AF; extends hiPSC-CM organoid models for mechanistic studies.
Atrial fibrillation (Afib) presents significant public health challenges due to its complex mechanisms and elevated risks of stroke and heart disease. This study employs 3D fast-paced organoid models derived from human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to investigate mitochondrial dysfunction and cardiac fibrosis in Afib at the molecular level. Rapid pacing at 3 Hz for 24 h triggered a 50 % decline in peak contraction amplitude and a 55 % reduction in contraction velocity. Multi-omics profiling revealed pronounced mitochondrial injury—succinate dehydrogenase sub-units SDHA–D decreased by 35–60 % and the master regulator PGC-1α fell 48 % together with a 2.3-fold increase in cytosolic cytochrome-c. Profibrotic signalling was activated in parallel (AGTR1 was up-regulated 2.1-fold, TGF-β1 was up-regulated 2.5-fold), driving extracellular-matrix accumulation (collagen-I and α-SMA levels rose 1.9- and 2.2-fold, respectively). Public Gene Expression Omnibus (GEO) datasets further validated the clinical relevance of our model; the organoid transcriptional fingerprint correlated strongly with human atrial-tissue fibrosis signatures (R = 0.71, p < 0.001; GSE128188), highlighting its translational value. Collectively, these quantitative data demonstrate that 3-D fast-paced organoids recapitulate both the functional impairment and synchronous mitochondrial-fibrotic remodeling characteristic of early Afib. Taken together, coupling high-resolution functional metrics with multi-omics read-outs elevates cardiac-disease modelling and can accelerate the development of targeted therapies for atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Son et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: